Trial Profile
The efficacy of Alirocumab for thin-cap fIbroatheroma in patients with coronary artery disease estimated by optical coherence tomography: Single centor, Randomized, Open-label, trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Rosuvastatin
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms ALTAIR
- 28 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Oct 2017 New trial record